French health authorities report medication shortages and supply tensions for several hospital-only drugs, affecting availability and requiring temporary imports from other countries.
French drug shortages reported
Between October 16 and October 29, 2026, the French National Agency for Medicines Safety (ANSM) reported disruptions or updated availability data for several medications that are only distributed through the hospital supply chain. These updates highlight ongoing challenges in maintaining a stable supply of critical drugs in French hospitals.Ambrisentan availability issues
Medications containing ambrisentan, a drug used to treat pulmonary arterial hypertension, are experiencing shortages or limited availability. The Spanish version of VOLIBRIS has been imported, while several brands like Viatris Santé, Teva, and GSK (VOLIBRIS) have reported stock shortages for specific dosages, including 5 mg and 10 mg tablets.Imported ambrisentan temporarily available
Some ambrisentan tablets have been temporarily made available in French hospitals through imports from other countries. For example, Ambrisentan Mylan 10 mg tablets were imported from Germany in July, and Ambrisentan Viatris tablets were brought in from Australia in September. These imports are expected to be available only temporarily.Scheduled return dates for ambrisentan
According to the ANSM, the Spanish version of VOLIBRIS 5 mg tablets will be available until mid-December 2026, while other ambrisentan formulations, such as AMBRISENTAN ACCORD and AMBRISENTAN VIATRIS, are expected to return in March 2027. These dates are based on supply chain planning and manufacturing schedules.Other medications in supply tension
Several other medications are also experiencing supply issues. BERIRAB, which replaces IMOGAM RAGE, is under tension, with a return date set for the end of November 2026. BREVIBLOC, an injectable medication, is in short supply, with temporary availability from the U.S. market expected to last until mid-2027.Clindamycin and calcium folinate updates
Clindamycin injectable solutions are partially available, but some formulations, such as CLINDAMYCINE KALCEKS, are in short supply. Calcium folinate injectable solutions are seeing a return to normal availability, though some specialties remain in tension. The return of these drugs is expected to be completed by mid-October 2026.Gilurytmal and linezolid shortages
GILURYTMAL, which replaces the discontinued CARDIORYTHMINE, is under supply tension, with a return date expected in early December 2026. Linezolid, used to treat bacterial infections, is also in short supply, with imports from Spain, Germany, and the Netherlands being used to meet urgent needs.Other affected medications
A range of other medications, including MIOCHOLE, MIOSTAT, OXYBATE DE SODIUM REIG JOFRE, PEDIAVEN AP-HP G15, PLERIXAFOR ARROW, and PLASMION, are also experiencing shortages or supply tension. Each has specific return dates or temporary availability based on imports and manufacturing schedules.
